Sanofi announced that the latest results of phase 2 clinical trials showed that after one year of Frexalimab monoclonal antibody treatment, the plasma levels of neurofilament light chain (NfL) decreased significantly (by 41%). The data indicates that people with relapsing multiple sclerosis (rMS) are expected to welcome a groundbreaking, efficient, and helpful treatment for improving their condition. The company is conducting phase 3 clinical trials around rMS and non-relapsing progressive multiple sclerosis (nrMS).
赛诺菲：临床试验中，单抗Frexalimab有助于NfL中的血浆水平“大幅”下降41%
In clinical trials, the Frexalimab monoclonal antibody helps the plasma levels of NfL to decrease by a significant 41%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.